Zymeworks Inc (ZYME)
9.58
-0.17 (-1.74%)
USD |
NYSE |
Jan 27, 16:00
9.50
-0.08 (-0.84%)
Pre-Market: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 554.61M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 15.42% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 17.58 |
Price to Book Value | 2.495 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 91.81% |
News
Headline
Wire
Time (ET)
MT Newswires
01/20 08:16
MT Newswires
01/19 12:27
PR Newswire
01/19 08:49
PR Newswire
01/19 07:45
SA Breaking News
01/13 15:00
MT Newswires
01/04 17:28
SA Breaking News
01/04 17:00
Events
DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
02/24/2023* | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
02/24/2023* | -- | Results | Q4 2022 | -- | 3.11 | -- | |
11/08/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
11/08/2022 | -- | Results | Q3 2022 | -- | -0.97 | -- | |
08/04/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
08/04/2022 | -- | Results | Q2 2022 | -0.97 | -0.94 | -2.75% | |
05/04/2022 | 16:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
05/04/2022 | -- | Results | Q1 2022 | -1.19 | -0.76 | -57.41% |
*Estimated Date/Time
Earnings
Profile
Edit
Zymeworks BC Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. |
URL | https://www.zymeworks.com |
Investor Relations URL | https://ir.zymeworks.com/ |
HQ State/Province | British Columbia |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | Feb. 24, 2023 (est.) |
Last Earnings Release | Nov. 08, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Dividends
Dividend Per Share (TTM) | -- |
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
Yield to Market | 0.00 |
Yield to Sector | 0.00 |
Yield to Industry | 0.00 |
Last Dividend Amt. | -- |
Dividend Frequency | -- |
Last Ex-Dividend Date | -- |
Yield (TTM) | 0.00% |
Forward Yield | -- |
Payout Ratio | 0.00% |
Cash Payout Ratio | 0.00% |
Consistent Payer (5Y) | No |
Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of January 27, 2023.
Fundamentals
Revenue (TTM) | 31.62M |
Total Expenses (TTM) | 271.98M |
Net Income (TTM) | -236.98M |
Total Assets (Quarterly) | 368.97M |
Total Liabilities (Quarterly) | 146.69M |
Shareholders Equity (Quarterly) | 222.28M |
Cash from Operations (TTM) | -211.53M |
Cash from Investing (TTM) | 39.15M |
Cash from Financing (TTM) | 113.56M |
Ratings
Profile
Edit
Zymeworks BC Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. |
URL | https://www.zymeworks.com |
Investor Relations URL | https://ir.zymeworks.com/ |
HQ State/Province | British Columbia |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | Feb. 24, 2023 (est.) |
Last Earnings Release | Nov. 08, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Risk Info
Ownership
Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Other Resources
Whale Wisdom | 13F Filings |
Seeking Alpha | Call Transcripts |
Nasdaq | Insider Trading |
Nasdaq | Institutional Ownership |
Nasdaq | Option Chain |
SEC | SEC Filings |
ZYME Tweets |